Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hyperliquid Strategies IncPURR · Entity 681 | Director | February 09, 2026 | February 11, 2026 |
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | October 26, 2017 | October 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hyperliquid Strategies Inc
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,671 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 40,789 · Balance 41,671 F1: Represents restricted stock units scheduled to vest over a three-year period, with one-third vesting on each of December 2, 2026, December 2, 2027 and December 2, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units scheduled to vest over a three-year period, with one-third vesting on each of December 2, 2026, December 2, 2027 and December 2, 2028.
Outlook Therapeutics, Inc.
Report date October 26, 2017 · Filed October 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-10-26 | Direct | 15,000 |
Reported balance
After 2017-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sonnet BioTherapeutics Holdings, Inc.
Report date December 02, 2025 · Filed December 04, 2025
Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-02 transaction · row 1
1 source rowRow 1 · 2025-12-02 · Disposition to issuer · Disposed 4,537 · Balance 0 F1: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2: (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. F3: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger").
F2: (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
F3: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 19:35 UTC | Hyperliquid Strategies Inc PURR · Entity 681 | GrantCommon Stock | 40,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047187 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,671 F1 · price: Represents restricted stock units scheduled to vest over a three-year period, with one-third vesting on each of December 2, 2026, December 2, 2027 and December 2, 2028. F1 · acquired: Represents restricted stock units scheduled to vest over a three-year period, with one-third vesting on each of December 2, 2026, December 2, 2027 and December 2, 2028. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 02:12 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | Disposition to issuerCommon Stock | 4,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-026062 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2 · shares: (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. F3 · shares: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. F1 · price: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2 · price: (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. Read SEC document |
| December 02, 2025 Filed Dec 23, 2025 13:03 UTC | Hyperliquid Strategies Inc PURR · Entity 681 | OtherCommon Stock | 882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-330461 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882 F1 · price: On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Mr. Albert Dyrness received 882 shares of common stock, par value $0.01 per share, of the Company, in exchange of certain securities of Sonnet Mr. Dyrness held prior to the Closing. Read SEC document |
| December 11, 2023 Filed Dec 6, 2024 02:55 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-048956 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537 F1 · price: On December 11, 2023, the Reporting Person was granted 373 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025. F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. Read SEC document |
| July 11, 2023 Filed Jul 15, 2025 23:35 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-019785 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,537 F1 · price: On July 11, 2025, the Reporting Person was granted 4,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on the earlier of (i) January 8, 2026, or (ii) the date of a "Change in Control" (as defined under the Issuer's 2020 Omnibus Equity Incentive Plan). F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. Read SEC document |
| May 30, 2023 Filed May 31, 2023 12:30 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 23,255 | $0.47 | $10,883.34 |
DisclosureSEC source: 0001493152-23-019539 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,962 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| December 14, 2022 Filed Dec 22, 2022 21:30 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 3,770 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-036313 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,893 F1 · shares: On December 14, 2022, the Reporting Person was granted 3,770 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F1 · price: On December 14, 2022, the Reporting Person was granted 3,770 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 15, 2021 Filed Apr 8, 2022 20:30 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 14,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-009486 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,123 F1 · shares: On December 15, 2021, the Reporting Person was granted 14,152 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. F1 · price: On December 15, 2021, the Reporting Person was granted 14,152 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 22:14 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 8,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012568 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,971 F1 · shares: On July 2, 2020, the Reporting Person was granted 8,005 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 50% of the restricted stock units on April 2, 2021 and 50% of the restricted stock units on April 2, 2022. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:05 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | PurchaseCommon Stock | 2,409 | $4.01 | $9,660.09 |
DisclosureSEC source: 0001493152-20-011085 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,966 Read SEC document |
| April 01, 2020 Filed Apr 4, 2020 00:59 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantWarrant to Purchase Common Stock · Derivative | 1,279 | Not disclosed Strike: $29.32 | Not disclosed |
DisclosureSEC source: 0001493152-20-005838 · ownership.xml · derivative · entry 2 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2022-12-03 F2 · price: Prior to the merger, Reporting Person held warrants to purchase 12,000 shares of the common stock of Sonnet Sub at an exercise price of $3.125 per share. Pursuant to the Merger Agreement, these warrants were converted into warrants to purchase 1,279 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $29.32 per share (as adjusted for the stock split). Read SEC document |
| April 01, 2020 Filed Apr 4, 2020 00:59 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 2,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-005838 · ownership.xml · nonDerivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,557 F1 · price: Shares of common stock of the corporation known as Sonnet BioTherapeutics, Inc. ("Sonnet Sub") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger, dated as of October 10, 2019, as amended, by and among the Issuer, Sonnet Sub and Biosub Inc., a Delaware corporation (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Sonnet Sub common stock was exchanged for approximately 0.106572 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Prior to the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 26 shares of Issuer common stock outstanding and the Issuer changed its name to Sonnet BioTherapeutics Holdings, Inc. All share numbers reflect the reverse stock split. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 22:01 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-17-058359 · doc4.xml · derivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-10-26 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 21:55 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | PurchaseWarrant (Right to Buy) · Derivative | 11,500 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001209191-16-156825 · doc4.xml · derivative · entry 1 Dyrness Albert D. · CIK 0001664801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2021-12-22 F2 · price: The Reporting Person acquired a Senior Secured Note in the principal amount of $50,000 together with a Warrant to purchase 11,500 shares of the common stock of the Issuer in exchange for the Reporting Person's Unsecured Bridge Note in the principal amount of $50,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.